Production of CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever. by Pannetier, Delphine et al.
Production of CXC and CC chemokines by human
antigen-presenting cells in response to Lassa virus or
closely related immunogenic viruses, and in cynomolgus
monkeys with lassa fever.
Delphine Pannetier, Ste´phanie Reynard, Marion Russier, Xavier Carnec,
Sylvain Baize
To cite this version:
Delphine Pannetier, Ste´phanie Reynard, Marion Russier, Xavier Carnec, Sylvain Baize.
Production of CXC and CC chemokines by human antigen-presenting cells in response to
Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa
fever.. PLoS Neglected Tropical Diseases, Public Library of Science, 2014, 8 (1), pp.e2637.
<10.1371/journal.pntd.0002637>. <hal-01011803>
HAL Id: hal-01011803
https://hal.archives-ouvertes.fr/hal-01011803
Submitted on 1 Jul 2014
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Production of CXC and CC Chemokines by Human
Antigen-Presenting Cells in Response to Lassa Virus or
Closely Related Immunogenic Viruses, and in
Cynomolgus Monkeys with Lassa Fever
Delphine Pannetier1,2., Ste´phanie Reynard1,3., Marion Russier1,3, Xavier Carnec4, Sylvain Baize1,3*
1Unite´ de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France, 2 Laboratoire P4 Inserm-Jean Me´rieux, US003, Lyon, France, 3Centre International de
Recherche en Infectiologie (CIRI), Universite´ de Lyon, INSERM U1111, Ecole Normale Supe´rieure de Lyon, Universite´ Lyon 1, CNRS UMR5308, Lyon, France, 4Unite´ de
Ge´ne´tique Mole´culaire des Bunyavirus, Institut Pasteur, Paris, France
Abstract
The pathogenesis of Lassa fever (LF), a hemorrhagic fever endemic to West Africa, remains unclear. We previously compared
Lassa virus (LASV) with its genetically close, but nonpathogenic homolog Mopeia virus (MOPV) and demonstrated that the
strong activation of antigen-presenting cells (APC), including type I IFN production, observed in response to MOPV probably
plays a crucial role in controlling infection. We show here that human macrophages (MP) produce large amounts of CC and
CXC chemokines in response to MOPV infection, whereas dendritic cells (DC) release only moderate amounts of CXC
chemokines. However, in the presence of autologous T cells, DCs produced CC and CXC chemokines. Chemokines were
produced in response to type I IFN synthesis, as the levels of both mediators were strongly correlated and the neutralization
of type I IFN resulted in an inhibition of chemokine production. By contrast, LASV induced only low levels of CXCL-10 and
CXCL-11 production. These differences in chemokine production may profoundly affect the generation of virus-specific T-
cell responses and may therefore contribute to the difference of pathogenicity between these two viruses. In addition, a
recombinant LASV (rLASV) harboring the NP-D389A/G392A mutations, which abolish the inhibition of type I IFN response by
nucleoprotein (NP), induced the massive synthesis of CC and CXC chemokines in both DC and MP, confirming the crucial
role of arenavirus NP in immunosuppression and pathogenicity. Finally, we confirmed, using PBMC samples and lymph
nodes obtained from LASV-infected cynomolgus monkeys, that LF was associated with high levels of CXC chemokine mRNA
synthesis, suggesting that the very early synthesis of these mediators may be correlated with a favourable outcome.
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Introduction
Lassa virus (LASV) is the causal agent of Lassa fever (LF), a
hemorrhagic fever endemic to West Africa [1]. The virus is
transmitted to humans through contact with infected Mastomys sp.,
rodents living close to housing and constituting a natural reservoir
of LASV. Human-to-human transmission then occurs through
mucosal/cutaneous contact. LF affects about 300,000 people each
year, resulting in 5,000–6,000 deaths. There is no approved
vaccine against the disease, and the only treatment available,
ribavirin, is neither fully effective nor useful in the field, due to its
limited availability and the need to initiate treatment soon after
infection [2]. LF is therefore a major public health concern in the
countries in which it is endemic, and this problem is exacerbated
by the tendency of the zone of endemicity to expand [3].
LASV is an Old World arenavirus from the Arenaviridae family.
It is an enveloped bisegmented RNA virus. Its small segment (S)
encodes the nucleoprotein (NP) and the glycoprotein precursor
(GPC) and is cleaved by the subtilase SKI-1/S1P to generate GP1
and GP2, mediating viral entry by binding to a-dystroglycan [4,5].
The large segment (L) encodes the RNA-dependent RNA
polymerase and the Z protein, a small zinc-binding protein
important for replication, transcription and viral budding
[6,7,8,9]. The pathogenesis of LF is poorly understood. Antigen-
presenting cells (APC), dendritic cells (DC) and macrophages (MP)
are the principal initial targets of LASV [10,11,12]. The first few
cycles of viral replication occur in these cells and the tropism of
LASV then widens, such that viral replication also occurs in
hepatocytes, endothelial cells, fibroblasts and some epithelial cells
[13,14]. However, changes to the liver, endothelium and other
organs are not severe enough to account for death, which occurs in
a context of hypoxic, hypotensive and hypovolemic shock. Little is
known about the immune responses associated with survival or
death after LF. The production of specific antibodies (Ab) is not
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correlated with survival, as such Ab are detected in all patients,
regardless of outcome [15]. Moreover, LASV does not induce the
production of neutralizing Ab [16,17]. Instead, protection seems to
depend on the induction of specific T-cell responses [17,18,19].
Mopeia virus (MOPV) is an Old World arenavirus closely
related to LASV. Indeed, MOPV is 60 to 80% identical to LASV
in terms of its nucleotide and amino-acid sequences and has also
been isolated from Mastomys natalensis [20,21,22]. However,
MOPV is nonpathogenic in non human primates (NHP), and
probably also in humans, and it can even immunize monkeys
against LASV [23]. We investigated the immune responses
associated with LF, by comparing the responses induced by these
two viruses in human in vitro models. The infection of DC leads to
the release of large amounts of LASV and MOPV, without
significant cell activation or cytokine production [10,24,25]. MP
were not activated by LASV infection, but strong activation and
significant amounts of type I IFN production were observed in
response to MOPV infection. We showed that viral tropism for
APC probably played a crucial role in pathogenesis. Indeed,
MOPV-, but not LASV-, infected DC induce robust primary
human T-cell responses in vitro [26].
The lack of induction of type I IFN production by LASV is due
to the presence in the C-terminal part of the NP of a dsRNA-
specific 39 to 59 exonuclease related to the enzymes of the DEDDh
family [27,28]. By digesting viral dsRNA, LASV escapes
recognition by the RIG-I and MDA-5 helicases, which have been
implicated in the sensing of arenavirus RNA and the induction of
type I IFN production [29]. The amino-acid residues involved in
this activity have been described and their mutation abolishes the
anti-IFN properties of NP [30]. The differences in pathogenicity
and type I IFN production between LASV and MOPV cannot be
due to exonuclease activity alone, as the DEDDh motif is also
present in the MOPV NP. The MOPV NP therefore probably
also inhibits type I IFN production, albeit less efficiently than the
LASV NP. We therefore used reverse genetics to generate a
rLASV containing mutations affecting the DEDDh motif. This
virus induced a much stronger type I IFN response than MOPV
[31]. In addition, it has recently been shown that the arenavirus
NP inhibits IRF3 phosphorylation and subsequent type I IFN
synthesis by sequestering the IkB kinase-related kinase IKKe in an
inactive form [32]. Finally, arenavirus NP has also been reported
to prevent the nuclear translocation of NFkB, consistent with the
lack of proinflammatory cytokine release observed in response to
LASV infection [33].
Inflammatory chemokines are crucial mediators in the develop-
ment of innate and adaptive immune responses and viral control,
but they may also participate in pathogenesis [34,35,36,37,38]. The
role of chemokines in LF is poorly understood. The release of
CXCL10 (IP-10) and IL-8 into plasma has been correlated with
survival in LASV-infected patients [39]. Consistent with this
finding, LASV-infected human monocytes/MP, unlike their
MOPV-infected counterparts, fail to produce IL-8 [40]. In addition,
no increase in plasma concentrations of CCL5 (RANTES), CXCL9
(MIG), CXCL-10, and IL-8 has been detected in moribund LASV-
infected cynomolgus macaques; CCL2 (MCP-1) was the only
chemokine circulating in significant quantities in these animals [11].
In another study in cynomolgus macaques, increases in the synthesis
of CXCL-10 and CXCL11 (I-TAC) mRNA were reported in
PBMC and lymph nodes, regardless of the outcome of infection
[17]. Finally, rhesus macaques intravenously infected with LCMV
as a surrogate for LF display high plasma concentrations of IL-8 and
CXCL10, together with strong synthesis of CXCL10 mRNA in
PBMC [41]. We compared the production of CC and CXC
chemokines by human DC and MP in response to infection with
LASV and MOPV, but also in response to infection with LASV-NP
D389A/G392A, a rLASV harboring mutations affecting the NP
exonuclease, preventing it from inhibiting type I IFN production.
We also confirmed that cynomolgus monkeys produced large
amounts of CXC chemokines in vivo during LF.
Materials and Methods
Viruses and cell lines
The AV strain of LASV, isolated from the serum of a patient
[42], and MOPV, strain AN 23166, isolated from Mastomys
natalensis [22], were subjected to four passages on Vero E6 cells at
37uC, under an atmosphere containing 5% CO2, in Dulbecco’s
modified Eagle medium supplemented with 50 IU/ml penicillin-
streptomycin, 1% non essential amino acids (all from Invitrogen,
Cergy-Pontoise, France) and AB+ human serum (Etablissement
Franc¸ais du Sang [EFS], Lyon, France). Cell-free supernatants were
harvested after three days for LASV infection and after four days
for MOPV infection, and were used as infectious virus stocks, with
a viral titer of 2.56107 FFU/ml. The rLASV NP-D389A-G392A
and wild-type rLASV were generated by reverse genetics
techniques, as previously described [31], and were passaged twice
on Vero E6 cells to obtain the viral stocks (1.26107 FFU/ml).
BSL-4 facilities (Laboratoire P4-INSERM Jean Me´rieux, Lyon)
were used for all experiments with LASV, whereas MOPV was
manipulated in BSL-2 facilities. Vero E6 cells and virus stocks
were not contaminated with mycoplasma.
Preparation of DC and MP
Monocytes and lymphocytes were isolated from the blood of
healthy human donors (EFS), as previously described [10,26].
Briefly, peripheral blood mononuclear cells (PBMC) were isolated
by density gradient centrifugation on Ficoll-Paque (GE-Healthcare
BioSciences AB). Autologous plasma (AP) was harvested, heated
for 30 min at 56uC and centrifuged for T cell experiments.
Monocytes were then separated from peripheral blood lympho-
cytes (PBL) by centrifugation on 50% Percoll (GE-Healthcare) in
PBS and purified by immunomagnetic depletion. PBL were frozen
in RPMI 1640-Glutamax I with 50 IU/ml penicillin-streptomy-
cin, 1% non essential amino acids, 10 mM HEPES (C-RPMI)
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Lassa virus (LASV) causes a viral hemorrhagic fever that
affects about 300,000 people and leads to 5,000 deaths
annually. Lassa fever (LF) is a public health problem in
West Africa, where it is endemic, because of the number of
cases, deaths and disabling effects. There is no vaccine
against LASV and the only treatment, ribavirin, is not useful
in the field. Little is known about the pathogenesis and
immune responses associated with LF. Chemokines are
involved in the induction of immunity and attraction of
immune cells to inflamed sites. We compared the ability of
antigen-presenting cells to produce chemokines in re-
sponse to infection with LASV, the closely related but
nonpathogenic Mopeia virus (MOPV) and a LASV unable to
inhibit the type I IFN response due to mutations in its
nucleoprotein gene. We found that MOPV and the mutant
LASV, but not wild-type LASV, strongly induced CC and
CXC chemokine production by dendritic cells and macro-
phages, in a type I IFN-dependent manner. We confirmed
in cynomolgus monkeys that these mediators probably
play a role during LF. These results highlight the role of
innate immunity in LF control and provide insight into the
mechanisms leading to survival or death after infection.
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supplemented with 20% AP and 10% dimethylsulfoxide (DMSO)
(Sigma-Aldrich, Saint-Quentin Fallavier, France) and 20% AP and
stored in liquid nitrogen. Cells were cultured in C-RPMI
supplemented with either 10% FCS for APC cultured alone or
10% AP for cultures containing autologous T cells in order to
prevent non specific stimulations (full-RPMI). iDC and MP were
differentiated from monocytes in full-RPMI supplemented with
2000 IU/ml recombinant human (rh) granulocyte-macrophage
colony-stimulating factor plus 1000 IU/ml rh interleukin (IL)-4 or
with 10 ng/ml rh macrophage colony-stimulating factor, respec-
tively (all from PeproTech, Rocky Hill, NJ, USA). Half the
cytokine content and 40% of the culture medium were replaced
every 48 h and cells were harvested six days later. In experiments
using T cells, two vials of DC were frozen in AP containing 10%
DMSO for subsequent re-stimulation.
Infection of DC and MP with LASV
DC and MP cell pellets were incubated with virus-free Vero E6
cell supernatant (mock infection) or infectious LASV or MOPV at
a multiplicity of infection of 2, for 1 h at 37uC, with regular
shaking. DC and MP were then washed and cultured (106 cells/
ml) in full-RPMI. In some experiments, the type I IFN receptor
was neutralized by adding antagonistic mAbs directed against
CD118, the beta chain of this receptor (5 mg/ml, PBL Biomedical
Laboratories, Piscataway, NJ).
Coculture of DC and T cells in vitro
We previously described an in vitro model of DC and T-cell co-
culture, with three rounds of stimulation [26]. The first round of
stimulation involved the infection of DC with infectious LASV or
MOPV. DC were then cocultured with autologous T cells at a
ratio of 1 DC to 10 T lymphocytes, at a density of 26105 and
26106 cells/ml, respectively. PBL were thawed and depleted of B
and NK cells as previously described [26]. The second and third
rounds of stimulation were carried out 9 and 19 days after the first
round of stimulation by culturing thawed iDC stimulated by
inactivated viruses or culture medium (mock) and T cells harvested
from the previous stimulation. We replaced 30% of the culture
medium with fresh medium every two or three days. On day 2 of
each round of stimulation, 10 IU/ml (for the first stimulation) or
5 IU/ml (second and third stimulations) of rhIL-2 and rhIL-7
(both from Peprotech) were added to the culture medium. In some
experiments, the type I IFN receptor was neutralized by adding
5 mg/ml antagonistic mAbs directed against CD118 (PBL
Biomedical Laboratories) every two days during the first round
of stimulation. Control cells were treated similarly, with an
irrelevant mouse IgG2a (R&D Systems, Lille, France).
Detection of mRNA by RT-PCR
Cellular RNAs were isolated from human cells and cynomolgus
monkey PBMC or lymph node cells and used for the synthesis of
first-strand cDNA as previously described [10,17]. In human
samples, mRNAs encoding cytokines were quantified by real-time
RT-PCR (RT-qPCR) with commercially available primers and
probes and TaqMan Universal Master Mix on an ABI PRISM
7000 real-time thermocycler and cDNA were amplified in duplex
with b-actin or GAPDH (all from Applied Biosystems). Other
TaqMan assays were carried out with the following primers and
probes: IFNb: 59-TCTCCACGACAGCTCTTTCCA-39 and 59-
ACACTGACAATTGCTGCTTCTTTG-39, probe: 59-AACT-
TGCTTGGATTCCT-39 ; IFNa1: 59-GTGGTGCTCAGCTG-
CAAGTC-39 and 59-TGTGGGTCTCAGGGAGATCAC-39,
probe: 59-AGCTGCTCTCTGGGC-39 ; IFNa2: 59-CAGTC-
TAGCAGCATCTGCAACAT-39 and 59-GGAGGGCCACCA-
GTAAAGC-39, probe: 59-ACAATGGCCTTGACCTT-39. C-
CL2, CCL3, CCL5, CXCL9, CXCL10, and CXCL11 mRNAs
were quantified in lymph node samples by RT-qPCR in a
LightCycler 480 thermocycler (Roche Diagnostic, Meylan, France),
using TaqMan Universal Master Mix and commercially available
primers and probes (all from Applied Biosystems), as well as the
following primers and probe for b-actin: 59-GCGCGGCTA-
CAGCTTCA-39 and 59-CTTAATGTCACGCACGATTTCC-
39, probe: 59-CACCACGGCCGAGC-39 . The cDNA obtained
from cynomolgus monkey PBMC mRNA was amplified on an ABI
Prism 7000 real-time thermocycler (Applied Biosystems) with SYBR
green PCR master mix (Applied Biosystems) and the following
primers: b-actin: 59-TGAACCCCAAGGCCAACC-39 and 59-
GCCAGCCAGGTCCAGACG-39; CXCL9: 59-GGAACCC-
CAGTAATGAGGAAGG-39 and 59-GCAGGAAAGGTTTGG-
AGCAA-39. CXCL10: 59-TGAAAAAGAAGGGTGAGAAGAG-
GT-39 and 59-TGATGGCCTTAGATTCTGGATTC-39; CXC-
L11: 59-TACGGTTGTTCAAGGTTTCCC-39 and 59-TGGAG-
GCTTTCTCAATATCTGC-39. The specificity of the amplicons
was checked by determining their melting temperatures.
The levels of cytokine mRNA relative to b-actin or GAPDH
mRNA levels for each sample (relative mRNA levels) were
calculated as follows:
D Cycle threshold (Ct) =Ct gene X - Ct b-actin or GAPDH
The ratio (mRNA of interest/b actin or GAPDH mRNA)=2 2DCt
ELISA detection of cytokines
Supernatants from cultures of DC and MP were harvested,
centrifuged and stored at 280uC. Commercial ELISA kits were
used for CCL2, CCL3, CCL4, CCL5, CCL7, CXCL9, CXCL10,
and CXCL11 detection, according to the manufacturer’s instruc-
tions (Bender MedSystems, Vienna, Austria; R&D Systems; BD
Biosciences; eBioscience, Paris, France). IFNa was assayed with a
human-specific ELISA set (Bender MedSystems), in serial plasma
samples obtained from LASV-infected cynomolgus monkeys and
control animals [17].
Infection of cynomolgus monkeys with LASV
Animal experiments were performed in the Jean Me´rieux –
INSERMBSL4 animal facilities using eight healthy male cynomolgus
monkeys (Macaca fascicularis) as previously described [17]. All the
procedures for animal handling were approved by the ‘‘ethics and animal
use committee of the Re´gion Rhoˆne-Alpes’’ (record Nu007) and performed in
accordance with the regulations of the ‘‘European Convention for the
Protection of Vertebrate Animals used for Experimental and Other Scientific
Purposes’’ (ETS nu123, French decree 2001/131). Briefly, six monkeys
were infected by low or high doses of LASV as specified and the other
two were mock infected and used as negative controls. PBMC were
isolated by density gradient centrifugation from blood or inguinal
lymph nodes, washed twice and cultured in full-RPMI.
Statistical analysis
Student’s t-test and Mann-Whitney were used to compare dataset
means. Differences were considered to be significant if the p value
was less than 0.05. Correlations were assessed by Spearman’s rank
correlation test. All statistical tests were performed with SigmaPlot
software (SyStat Software Inc, San Jose, CA, USA).
Results
Antigen-presenting cells produce type I IFN and
chemokines in response to MOPV, but not LASV
Our findings confirm previous reports [24,25] that MP and, to a
lesser extent DC, produce significant amounts of IFNb, IFNa1
CC and CXC Chemokines and Lassa Virus Infection
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and IFNa2 mRNA in response to MOPV infection. By contrast,
LASV-infected DC did not synthesize large amounts of these
mRNAs and in LASV-infected MP, only moderate levels are
produced (figure 1A). We then quantified the mRNAs encoding CC
and CXC chemokines in infected DC andMP. The infection of DC
with LASV orMOPV did not lead to synthesis of the CCL2, 3, 4, 5,
7, 13, and 17 mRNAs (data not shown), whereas an increase in the
levels of the mRNAs encoding CXCL9, 10, and 11 was observed in
MOPV-infected DC, but not in LASV-infected DC (figure 1B). The
infection of MP with MOPV induced robust expression of the
CCL2, 3, 4, 5, 7, and 13 genes, and of the CXCL9, 10, and 11
genes, in particular (figure 1C). By contrast, the infection of MP with
LASV did not result in the transcription of chemokine genes and
only CXCL10 and 11 mRNA are significantly produced. Thus, MP
and, to a lesser extent, DC, produce type I IFN and chemokines in
response to infection with MOPV, but not LASV.
Macrophages release large amounts of chemokines in
response to MOPV
The amounts of chemokines released into the culture superna-
tants were then assessed by ELISA. The results were consistent
with mRNA findings, as large amounts of the CC chemokines
CCL3, 4, 5, and 7 and, particularly, of the CXC chemokines
CXCL9, 10, and 11 were observed 24 and/or 72 h after the
infection of MP with MOPV (figure 2A). By contrast, MOPV-
infected DC produced only moderate amounts (although signif-
icantly higher than those for mock-infected cells) of CXCL10 (data
not shown and figure 2B). LASV-infected DC and MP produced
only modest amounts of CXCL10, and LASV-infected MP
produced only small amounts of CCL4.
Chemokine production by DC cultured with autologous
T cells and relationship to type I IFN production
We recently described an in vitro model of the induction of
primary human T-cell responses by LASV- and MOPV-infected
DC [26]. Using this model, we demonstrated that MOPV-infected
DC induced robust CD4+ and CD8+ T-cell responses involving
memory and cytotoxic T cells. By contrast, LASV-infected DC
failed to induce significant T-cell responses. We also observed that
the presence of T cells in MOPV-infected DC cultures signifi-
cantly increased the amount of type I IFN produced. We therefore
quantified chemokine production in this model. Two days after the
first round of stimulation, moderate but significant levels of CCL2,
3, 4, and 5 mRNA were detected in MOPV-infected DC cultured
with T cells, but not in LASV-infected DC, other than for CCL5
mRNA synthesis, which was slightly stronger in these cells than in
mock-infected cells (figure 3A). CCL7 mRNA levels in MOPV-
infected DC were about 10 times higher than those in mock- and
LASV-infected DC. Infection with MOPV induced the massive
synthesis of CXCL10 and 11 mRNA in DC, whereas only modest
levels of CXCL11 mRNA were detected in response to LASV
stimulation. By contrast, CXCL9 mRNA levels were not
significantly affected by infection with either virus (data not
shown). No further significant increase in mRNA synthesis was
observed after the second and third rounds of DC stimulation with
inactivated viruses (data not shown), other than for CXCL10
mRNA synthesis, which persisted in MOPV-stimulated DC and
was significantly induced after the second stimulation with LASV
(figure 3A). The levels of CCL4, CCL5, CCL7, CXCL10, and
CXCL11 in supernatants were significantly higher in MOPV-
infected DC than in mock- or LASV-infected DC cultured with T
Figure 1. Production of type I IFN and chemokine mRNA in DC and MP infected with LASV and MOPV.We obtained mRNA from DC and
MP 24 h after infection with LASV (black bars), MOPV (gray bars), or after mock infection (white bars). (A) The amounts of type I IFN mRNA produced
by DC and MP are shown as a gene mRNA/b-actin mRNA ratio. The synthesis of chemokine mRNA was evaluated with the GAPDH gene used as a
housekeeping gene, in both DC (B) and MP (C). Results are expressed as the mean 6 standard error (SE) of 4 and 5 independent experiments, for
LASV- and MOPV-infected cells, respectively. Significant differences between mock- and virus-infected cells are indicated as follows: * (p,0.05), **
(p,0.01), and *** (p,0.001).
doi:10.1371/journal.pntd.0002637.g001
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cells (figure 3B). In contrast, the increase in CCL2 levels in MOPV-
infected DC/T cell cocultures was not significant and no difference
was observed for CCL3 release in supernatants between mock-,
MOPV- and LASV-infected DC/T cell cocultures (data not shown).
Finally, the increase in CCL4, CCL7, CXCL10, and CXCL11
expression was strongly correlated with the intensity of IFNb, a1, and
a2 mRNA synthesis in LASV- and MOPV-infected DC (figure 3C).
Type I IFN is involved in the induction of chemokine
production by MOPV-infected DC
For confirmation of the involvement of type I IFN in the
observed production of chemokines by MOPV-infected DC
cultured in the presence of autologous T cells, we neutralized
the type I IFN response by adding a neutralizing antibody against
CD118, the b chain of the type I IFN receptor, during the first
round of T-cell stimulation with MOPV-infected DC and
analyzing the synthesis of chemokine mRNA after the first and
second stimulations. Neutralization of the type I IFN response
abolished the synthesis of the CCL4, CCL7, CXCL10, and
CXCL11 mRNAs induced by the first round of stimulation with
MOPV-infected DC (figure 4A), and that of the CCL2, CCL3,
and CCL5 mRNAs (data not shown). The increase in the synthesis
of the CCL4, CCL7, CXCL10 and CXCL11 mRNAs induced by
the second round of stimulation with MOPV was not significant,
and neutralization of the type I IFN response during the first
round of stimulation clearly abolished this overexpression
(figure 4B). Similar results were obtained for the CCL2, CCL3,
and CCL5 mRNAs (data not shown).
The recombinant LASV NP-D389A/G392A is a strong
inducer of CC and CXC chemokines
We recently described a rLASV harboring mutations affecting
the exonuclease site of the NP and abolishing the inhibition of the
type I IFN response by LASV [31]. We investigated the
involvement of the immunosuppressive properties of the LASV
NP in the defective production of chemokines by infected APC, by
evaluating chemokine production in NP-D389A/G392A (rNP)
LASV-infected APC and comparing the results obtained with
those for recombinant wild-type (rWT) LASV. Consistent with the
results obtained with LASV (figure 1B and data not shown), no
significant increase in the production of CC and CXC chemokine
mRNA and proteins was observed in rWT LASV-infected DC
(figure 5A and B). By sharp contrast, a robust increase in the
amounts of CCL2, CCL4, CCL5, CXCL9, CXCL10, CXCL11
mRNAs was detected in rNP LASV-infected DC and these
chemokines were significantly released in large amounts in the
culture supernatants. Interestingly, mRNA levels were even higher
than those obtained in MOPV-infected DC.
The amounts of CC and CXC chemokines produced were
similar in rWT LASV-infected MP (figure 5C and D) and in
LASV-infected MP (figure 1C). The infection of MP with rNP
LASV led to a robust and significant increase in the synthesis of
CCL2, 4, 5, and 7, and of CXCL9, 10, and 11 mRNA and to a
strong release of these chemokines in the culture supernatants, as
shown by comparison with mock-infected cells. Levels of mRNA
and proteins were also significantly higher than those observed in
rWT-infected MP, except for CCL2.
Strong synthesis of CXC chemokines is induced in PBMC
and lymph nodes during Lassa fever in cynomolgus
monkeys
We investigated whether chemokines were also produced in vivo
during LF, by evaluating the synthesis of mRNAs encoding CC
and CXC chemokines in samples obtained from cynomolgus
monkeys infected with LASV. We used mRNA extracted from
PBMC obtained from serial blood samples collected during the
course of infection and from lymph nodes removed nine days after
infection, from three monkeys infected with 103 FFU and three
monkeys infected with 107 FFU of LASV. As previously reported,
two of the three animals infected with low doses died, 16 and 21
days after infection, whereas all the monkeys infected with high
doses survived acute LF [17].
Figure 2. Release of chemokines into the supernatants of DC and MP infected with LASV and MOPV. The levels of CC and CXC
chemokines were quantified by ELISA in the supernatants of MP (A) and DC (B) 24 and 72 h after mock (white bars), MOPV (gray bars), and LASV
(black bars) infection. Results are expressed in pg/ml and ng/ml for CC and CXC chemokines, respectively. Significant differences are indicated as
follows: * (p,0.05), ** (p,0.01), and *** (p,0.001).
doi:10.1371/journal.pntd.0002637.g002
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We compared the results obtained for both PBMC and lymph
nodes with those obtained for these samples from the two mock-
infected monkeys. Levels of CCL2, CCL3, CCL4, CCL5 and
CCL7 mRNA synthesis in the infected monkeys were no higher
than those in the mock-infected monkeys (data not shown). By
contrast, increases in the amounts of mRNA encoding CXCL9,
CXCL10 and CXCL11 were detected in PBMC during the course
of the disease, and in the lymph nodes of all infected monkeys
(figure 6A and B and [17]). CXCL10 and CXCL11 mRNA
synthesis in PBMC was most marked six days after infection, in all
infected monkeys (figure 6A and [17]). However, three days after
infection, these mRNAs were considerably more abundant in
survivors than in the monkeys that subsequently died. These
outcome-associated differences were no longer evident six days
after infection and were not detected at any other point in the
course of the disease.
Finally, the increase in mRNA levels for CXCL10 and
CXCL11 and, to a lesser extent, CXCL9, in PBMC was strongly
Figure 3. Production of chemokines by MOPV- and LASV-infected DC cocultured with T cells and correlation with type I IFN
synthesis. (A) Levels of CC chemokine and CXCL11 mRNA were quantified relative to GAPDH mRNA levels, after 2 days of coculture of mock- (white
bars), MOPV- (gray bars), or LASV- (black bars) infected iDC and autologous T cells. Levels of CXCL10 mRNA were evaluated in iDC/T cell coculture 2
days after each stimulation of the T cells with infected or inactivated virus-stimulated iDC. Results are expressed as the mean6 standard error (SE) of
4 independent experiments. Significant differences are indicated as follows: * (p,0.05) and ** (p,0.01). (B) The levels of CC and CXC chemokines
were quantified by ELISA in the supernatants after 2 days of coculture of mock- (white bars), MOPV- (gray bars), or LASV- (black bars) infected iDC and
autologous T cells. Results are expressed in pg/ml, except for CXCL10 expressed in ng/ml. Significant differences are indicated as follows: * (p,0.05).
(C) Correlation between CCL4, CCL7, CXCL10, and CXCL11 mRNA levels and type I IFN synthesis by MOPV- or LASV-infected iDC cultured with naı¨ve T
cells 2 days after infection, represented by a linear regression with a correlation coefficient r and a probability of correlation p.
doi:10.1371/journal.pntd.0002637.g003
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correlated with the levels of IFNa release into the plasma of the
animals (as reported in [17]) during the course of LASV infection
(Figure 6C).
Discussion
Little is known about the pathogenesis of LF and the immune
responses that allow a substantial number of patients to recover
from acute hemorrhagic fever or even to control viral replication
without developing symptoms. We have developed in vitro models
for studying the response of human immune cells to infection with
the closely related arenaviruses LASV and MOPV, for the
identification of host parameters associated with virulence (LASV)
or an absence of pathogenicity (MOPV) [10,24,25,26,43]. We
have also recently developed reverse genetics techniques for
characterizing the role of viral factors in the pathogenicity of
LASV [31]. Here, we compare the abilities of LASV and MOPV
to induce the production of CC and CXC chemokines in human
APC, cultured alone or in the presence of T cells. Our findings
provide confirmation in vivo, in NHP, that LF is associated with
CXC chemokine release.
We found that MOPV induced a massive release of CC and,
more particularly, of CXC chemokines in MP. By contrast,
significant, but modest, increases in mRNA production in response
to infection were observed only for CXCL10 and CXCL11 in
LASV-infected MP. This striking difference in the response of MP
to infections with LASV and MOPV is consistent with our
previous finding that these cells are strongly activated by MOPV,
but not by LASV [24,25]. The cells potentially targeted by these
chemokines express CCR1, CCR2, CCR5 and CXCR3; they are
thus mostly monocytes, MP, iDC, activated T cells, Th1 cells, B
cells, and NK cells [44]. The release of substantial amounts of
chemokines by MOPV-infected MP may play a crucial role in the
lack of pathogenicity associated with this virus. Indeed, these
mediators may act at several levels in the control of viral infection.
First, most of the CC chemokines described here are involved in
the induction of innate responses through the recruitment of
inflammatory cells, mostly iDC and MP, to the site of infection for
the establishment of a local inflammatory response [45,46,47]. CC
chemokines, such as CCL2, 3, 4, 5 and 7, are also involved in
attracting naı¨ve and activated CD4+ and CD8+ T cells and
bringing them into contact with antigen-presenting DC
[34,48,49,50,51]. CXCL9, CXCL10 and CXCL11 are also
crucial for the induction of immune responses. Indeed, these
CXC chemokines are recognized by CXCR3, a receptor
specifically expressed by activated T lymphocytes and, to a lesser
extent, NK cells, but not resting T cells [52,53]. CXCL9, 10 and
11 are therefore major attractors of activated T cells, mostly Th1
and CTL, and they mediate the recruitment of effector T cells and
NK cells in secondary lymphoid organs and inflamed tissues
[54,55,56,57]. These chemokines have also been reported to
stimulate T-lymphocyte proliferation and effector cytokine pro-
duction [58]. Overall, these results suggest that the production of
CXC chemokines may be beneficial, helping to combat viral
infection [59]. However, an involvement of these chemokines in
immunopathological events has also been reported in some viral
infections [38,60], and further investigations are required to clarify
the role of CXC chemokines during LF, as we found that LASV
also induced the release of significant quantities of CXCL10 and
11 in vitro in MP and in vivo in NHP. The production of these
mediators in lymph nodes seemed to be more elevated 9 days after
infection in fatally-infected animals than in survivors. Although
this difference was noticeable in only one fatality, it would be
interesting to investigate whether there are higher amounts of
chemokines released in secondary lymphoid organs during severe
LF in comparison with non fatal infection and whether these
mediators play a deleterious role in this case.
The role of chemokines in LF in humans and relevant NHP
models remains unclear. Serum concentrations of IL-8 (CXCL8)
and CXCL10 have been shown to be higher in patients surviving
acute LF than in those who die, whereas CCL5 concentrations are
high in both groups [39], suggesting a possible beneficial effect of
CXC chemokines on outcome. Fatal LASV infection in cynomol-
gus monkeys has been associated with high plasma concentrations
of CCL2 and eotaxin in the absence of CCL5, CXCL9 and
CXCL10 release [11]. A transcriptomic analysis on PBMC from
cynomolgus monkeys fatally infected with LASV by aerosol
recently reported the upregulation of CCL23, CCRL2, IL-8 and
CXCL12 mRNA synthesis [61]. We did not detect the synthesis of
CC chemokines in our cynomolgus monkeys infected with LASV,
which is not consistent with the results obtained with MOPV or
rLASV NP389A/D392A. This discrepancy is unclear but may be
linked to the lack of MP in PBMC and to their limited proportion
among splenocytes, as these cells were the main source of CC
Figure 4. Role of type I IFN in the production of chemokines in MOPV- and LASV-infected iDC/T-cell cocultures. (A) The synthesis of
mRNAs for CCL4, CCL7, CXCL10 and CXCL11 was evaluated in mock- (gray bars) or MOPV- (black bars) infected iDC cocultured with naı¨ve T cells for 2
days in the presence of neutralizing Ab against CD118. (B) The levels of these mRNAs then were quantified 2 days after restimulation with mock- (gray
bars) or inactivated MOPV- (black bars) pulsed iDC of T cells previously cocultured with mock- or MOPV-infected iDC in the presence of irrelevant
IgG2a or CD118-neutralizing Ab. Results are expressed as the mean 6 SE of 3 independent experiments.
doi:10.1371/journal.pntd.0002637.g004
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chemokines in vitro. In any case, the putative protective role of CC
chemokines in LF should be interpreted according to this apparent
lack of in vivo production. In contrast, we did observe an increase in
mRNA levels for CXCL9, 10 and 11, in both PBMC and lymph
nodes (this report and [17]). No significant difference in mRNA
levels during acute disease was detected between lymph nodes (9
days after infection) and PBMC (from 6 days after infection).
However, very shortly after infection (3 days after infection),
during the incubation period, CXCL10 and CXCL11 mRNA
levels were found to be higher in the PBMC of the monkeys that
subsequently survived the acute infection than in the PBMC of
monkeys that died. These results have to be confirmed, as the
number of animals included here was very low and because the
chemokine levels have not been evaluated in lymph nodes at this
early time. Nevertheless, these results are consistent with the
higher levels of IL-8 (CXCL8) and CXCL10 detected in serum
Figure 5. Production of chemokines by APC infected with recombinant LASV. The production of CC and CXC chemokines by DC (A, B) and
MP (C, D) was assessed after mock infection (white bars), or infection with recombinant wild-type LASV (gray bars) or rLASV NP-D389A/G392A (rNP
LASV) (black bars). (A, C) The synthesis of mRNAs was analyzed by RT-qPCR 24 h after infection. (B, D) The protein levels released in the supernatants
were quantified by ELISA 24 h (only for CXCL9, 10 and 11) and 48 h after infection. Results are expressed as the mean 6 SE of 4 (A, C) and 3–7 (B, D)
independent experiments. Significant differences are indicated as follows: * (p,0.05), ** (p,0.01) and *** (p,0.001).
doi:10.1371/journal.pntd.0002637.g005
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samples from patients surviving acute LF than in those from
patients who die [39], suggesting that CXC chemokines may be
beneficial for outcome, particularly during early stages of the
disease. However, the evaluation of the overall production of
chemokines in patients would be required to determine whether
there is a correlation between the severity of LF and the
production of chemokines. If it be so, it would be important to
understand why different chemokine responses are induced by the
same virus in patients. The mechanisms that lead to the diversity
of clinical presentation of LF in humans ranging from subclinical
infection to catastrophic illness and death, are not clarified. These
different outcomes could be due to the type of cells early targeted
by the virus, the route of infection, the inoculum dose, preexisting
immunity against LASV or heterologous immunity, a different
immunological status at the time of infection or a genetic
background (HLA). LF was characterized by a massive, general-
ized infiltration of mononuclear cells, mostly macrophages, into
the tissues and organs of cynomolgus monkeys [17]. These cells
Figure 6. Production of CXC chemokine mRNA in PBMC and lymph nodes from LASV-infected cynomolgus monkeys. (A) The
synthesis of CXC chemokine mRNA was assessed by RT-qPCR, with normalization against b-actin mRNA in PBMC obtained from fatally infected
monkeys (red squares), the low dose-infected survivor (green squares) and the high dose-infected survivors (blue circles), at various times after
infection. The mRNA levels in the two mock-infected animals are represented as the mean (solid line) 6 SE (hashed line) of the values obtained
throughout follow-up (n= 14). (B) The production of these mRNAs was also quantified in lymph nodes obtained 9 days after infection. The levels of
mRNA are represented as the mean 6 SE of 4 samples for mock-infected animals (two animals, lymph nodes obtained 9 days after infection and at
necropsy) and as individual values for the two fatally infected monkeys (fatal inf.), the low dose (103 FFU)-infected survivor and the three high dose
(107 FFU)-infected survivors. The mean value 6 SE for all infected animals is shown, together with the significant difference between mock- and
LASV-infected animals. C) Correlation between CXCL9, CXCL10 and CXCL11 mRNA levels in PBMC and type I IFN levels in plasma during the course of
LASV infection in cynomolgus monkeys, represented by a linear regression with a correlation coefficient r and a probability of correlation p.
doi:10.1371/journal.pntd.0002637.g006
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could potentially be the source of CXC chemokines, attracting
activated T cells and NK cells to sites of inflammation. It is
possible that the rapidity with which this innate response is
established determines whether the disease is fatal or has a
favorable outcome. However, the mechanisms leading to a rapid
response in some animals and a slower response in others remain
unclear, and further investigations of this aspect are required.
The production of CCL4, CCL7, CXCL10 and CXCL11 in
LASV- and MOPV-infected DC cultured in the presence of
autologous T cells was strongly correlated with type I IFN synthesis,
and neutralization of the type I IFN receptor completely abolished
the release of these chemokines. Chemokine production was
inhibited during the first coculture in the presence of type I IFN
receptor-neutralizing antibodies, but also after the second stimula-
tion of T cells with MOPV-pulsed DC. The lack of type I IFN and/
or chemokines during the first round of T-cell stimulation with
MOPV-infected DC therefore had major consequences for the
priming of T cells, altering their ability to activate iDC during the
second round of stimulation. These results suggest that these
mediators play a crucial role in the induction of adaptive T-cell
responses to MOPV and provide additional evidence in favor of a
beneficial role of chemokines during arenavirus infection. The
ability of type I IFN to stimulate the production of CXC
chemokines, such as CXCL10 and CXCL11 in particular, is well
documented [62]. This close link between type I IFN and CXC
chemokine production was also observed in vivo, in our primate
model. In particular, the early release of IFNa observed specifically
in the plasma of the monkeys that survived and not in those that
died [17], is consistent with the increase in CXCL10 and CXCL11
mRNA levels in PBMC. The different production of type I IFN
observed between surviving and fatally-infectedmonkeys despite the
presence in animals of a virus presenting similar ability to inhibit this
response is unclear. One hypothesis could be that the early type I
IFN release observed in surviving primates was due to plasmacytoid
DC (pDC), as pDC activation following viral infection is mediated
by different TLR than myeloid DC or MP. Indeed, the ability of
mouse pDC to bind LASV GP and to release type I IFN after
infection with LCMV has been recently reported [63], suggesting
that these cells could play a crucial role in the induction of immune
responses during LF. Further investigations are required to confirm
this hypothesis in vivo and, if it occurs, to explain the activation of
these cells in some animals only. In addition, it would be important
to evaluate the ability of pDC to produce chemokines after
arenavirus infection to better understand the role of these cells
during infection. Nevertheless, these results suggest that the different
responses of APC toMOPV and LASVmake amajor contribution to
the difference in pathogenicity between these viruses and to the
crucial role of an early activation of innate immunity to the induction
of a successful adaptive response and survival in LF. Although the
rLASV NP-D389A/G392A is severely attenuated in APC [31],
LASV and MOPV replicate at similar levels in APC [10,25],
suggesting that the different chemokine responses are not related to
different amounts of viral particles released. Further evidence of the
correlation between type I IFN and chemokine responses was
provided by the analysis of APC responses to infection with our
rLASV NP-D389A/G392A. This LASV bears mutations abolishing
the function of the exonuclease domain of the NP; it therefore
strongly induces type I IFN production [31]. Consequently, the levels
of production of CC and CXC chemokines by MP infected with this
virus reached those observed with MOPV. More interestingly,
whereas only modest levels of CXC chemokines and no significant
synthesis of CC chemokines were induced in MOPV-infected DC,
large amounts of mRNAs encoding all these chemokines were
observed in response to the rLASV. Despite the presence of the
exonuclease site, which is conserved among arenavirus [64], in
MOPVNP, this virus is however able to induce substantial type I IFN
responses in APC. Several hypotheses can explain this observation.
Other inhibitory properties have been linked to arenavirus NP, such
as the ability to sequester IKKe in an inactive form or to inhibit
NFkB activation [32,33]. It is therefore possible that the efficiency of
the exonucleases to digest RNA or of these other inhibitory properties
of the NP is different between both viruses. In addition, the role of
other viral proteins such as the Z protein in immunosuppression
cannot be excluded. These results confirm the central role of NP in
the pathogenicity and lack of immunogenicity of LASV, and
demonstrate that the ability of LASV NP to inhibit type I IFN
induction has profound consequences for the innate, and probably
also adaptive, immune responses directed against LASV.
In summary, we show here, in both in vitro and in vivomodels, that
CC and CXC chemokines, including CXCL10 and CXCL11 in
particular, are probably key mediators during LF. Our results
suggest that the production of these molecules is associated with the
lack of pathogenicity of MOPV and with the immunogenicity of
LASV NP-D389A/G392A, and that their early release during the
incubation period is associated with the control of LASV infection in
NHP. Finally, we show that APC must produce type I IFN if they
are to release chemokines, and this requirement for type I IFN
seems to hold for cynomolgus monkeys. Further investigations in
NHP will nevertheless be required, to confirm the protective role of
these mediators and to elucidate their mode of action.
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